Suppr超能文献

过氧化物酶体增殖物激活受体配体在癌症化学预防中的应用。

PPAR Ligands for Cancer Chemoprevention.

机构信息

Department of Oncologic Pathology, Kanazawa Medical University, 1-1 Daigaku, Uchinada, Ishikawa 920-0293, Japan.

出版信息

PPAR Res. 2008;2008:548919. doi: 10.1155/2008/548919.

Abstract

Peroxisome proliferators-activated receptors (PPARs) that are members of the nuclear receptor superfamily have three different isoforms: PPARalpha, PPARdelta, and PPARgamma. PPARs are ligand-activated transcription factors, and they are implicated in tumor progression, differentiation, and apoptosis. Activation of PPAR isoforms lead to both anticarcinogenesis and anti-inflammatory effect. It has so far identified many PPAR ligands including chemical composition and natural occurring. PPAR ligands are reported to activate PPAR signaling and exert cancer prevention and treatment in vitro and/or in vivo studies. Although the effects depend on the isoforms and the types of ligands, biological modulatory activities of PPARs in carcinogenesis and disease progression are attracted for control or combat cancer development. This short review summarizes currently available data on the role of PPAR ligands in carcinogenesis.

摘要

过氧化物酶体增殖物激活受体(PPARs)是核受体超家族的成员,有三种不同的亚型:PPARα、PPARδ 和 PPARγ。PPARs 是配体激活的转录因子,与肿瘤的发生、分化和凋亡有关。PPAR 亚型的激活既具有抗癌作用,又具有抗炎作用。目前已鉴定出许多 PPAR 配体,包括化学组成和天然存在的配体。PPAR 配体被报道能激活 PPAR 信号通路,并在体外和/或体内研究中发挥预防和治疗癌症的作用。尽管作用取决于亚型和配体的类型,但 PPAR 在癌症发生和疾病进展中的生物学调节活性受到控制或对抗癌症发展的关注。这篇简短的综述总结了目前关于 PPAR 配体在癌症发生中的作用的可用数据。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/49b1/2377329/7fa985796fb2/PPAR2008-548919.001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验